We describe a case of 72-year-old female patient diagnosed with multiple myeloma (MM) in 2023, who presented with generalized fatigue. Patient was found to have elevated liver enzymes on biochemical workup. Her hepatotoxicity was attributed to Bortezomib therapy after ruling out other etiologies. Initially, patient's liver enzymes were normal prior to Bortezomib initiation. However, her liver enzymes started trending up at day 3 during her second session of Bortezomib. Liver function tests normalized 2 weeks after discontinuing Bortezomib. This fact points to a drug-induced liver injury (DILI) whereby Bortezomib is the likely culprit. Patient was started on thalidomide-containing regimen thereafter. Her liver enzymes remained within normal range following thalidomide-based regimen.
No takes yet. Share an insight, caveat, or question.
Karam et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: